Veradermics Widens Loss as Commercial Spending Ramps Up
Cash and securities reached $819.9 million after a May financing.
Veradermics (MANE), a clinical-stage drug developer, widened its quarterly net loss 50% to $23.5 million from $15.6 million a year earlier.
The larger loss reflected rising clinical-development costs and a sharp increase in commercial-readiness spending as Veradermics advanced its lead hair-loss treatment, VDPHL01.
Total operating expenses rose 84% to $29.6 million from $16.1 million, more than doubling the operating loss to $29.6 million from $16.1 million.
Research-and-development expense increased 30% to $18.6 million, driven by VDPHL01 clinical development, higher headcount and stock-based compensation. General-and-administrative expense climbed to $10.9 million from $1.7 million as personnel costs, commercial-readiness work and professional fees increased.
Other income rose to $6.1 million from $0.4 million, partly offsetting the higher operating loss. Interest income accounted for $4.8 million, up from $0.1 million a year earlier.
Study 306 completed enrollment of 556 women, marking further progress since the company's July clinical-results release. Veradermics continues to expect topline data in the first half of 2027.
Cash, cash equivalents and marketable securities increased $678 million from year-end, supported by about $472 million in gross proceeds from May's follow-on offering and concurrent private placement. Funds are expected to support operations into 2030, extending its runway beyond the anticipated Study 306 readout.